Utah Medical Products Inc. filings document formal disclosures for a Utah-incorporated medical device manufacturer whose common stock trades on Nasdaq under the symbol UTMD. Recent Form 8-K reports furnish quarterly and annual financial information, including sales, margins, earnings measures and exhibits containing the company's financial-performance releases.
The filing record also covers governance and capital-return matters. Definitive proxy materials describe director elections, auditor ratification, advisory executive-compensation votes and annual meeting procedures, while 8-K reports record stockholder voting results, board appointments, committee service, director compensation arrangements and quarterly dividend announcements.
Utah Medical Products, Inc. approved a regular quarterly cash dividend of $0.315 per share. The dividend is payable January 5, 2027, to shareholders of record at the close of business December 17, 2026.
Utah Medical Products Inc. (UTMD) Chairman, CEO Kevin L. Cornwell reported an indirect purchase of 1,000 common shares at $66.75 per share on October 29, 2026. His reported holdings following the transaction were 189,472 shares. The holdings listed include 6,000 shares in his own IRA, 128,478 in the Cornwell Bypass Trust and 54,994 in the Cornwell Survivor's Trust. No Rule 10b5-1 plan is reported.
Utah Medical Products, Inc. (UTMD) completed its issuer tender offer, purchasing 327,740 shares at $75.00 per share for $24,580,500. The offer was for up to 650,000 shares, or such lesser number as were validly tendered and not withdrawn, and expired October 27, 2026.
The company reported an effective cost of $75.35 per share and 2,849,041 shares outstanding as of October 29, 2026, including 1,775 employee option shares exercised in October. Administration and information-agent fees were $107,720, SEC filing fees were $6,732, and a 1% federal excise tax will be levied on share repurchases.
Utah Medical Products, Inc. (UTMD) reported third-quarter 2026 sales of $8.621 million, down 12.1% year over year, while net income rose 5.9% to $2.787 million and diluted EPS increased 6.8% to $0.876. Operating income increased 7.0% to $2.795 million. Lower sales from two former major customers and weaker Filshie Clip System sales weighed on revenue. Femcare Ltd. acquired Orion Medical Supplies at the end of August for $5.011 million, including legal costs and stamp duties; Orion added $619,000 in third-quarter sales.
For the first nine months, sales fell 12.2% to $25.873 million, net income decreased 7.4% to $8.077 million, and diluted EPS declined 5.3% to $2.537. Gross margin was 56.1% in Q3 versus 57.1% a year earlier; lower intangible-asset amortization helped operating income despite lower sales. At September 30, 2026, cash and investments were $85.202 million and UTMD reported no debt. Management projected full-year 2026 consolidated sales to decline close to 7%, with continued uncertainty.
Utah Medical Products, Inc. (UTMD) extended the expiration date of its issuer tender offer from October 7, 2026, to October 27, 2026. The company offers to purchase up to 650,000 shares of common stock at $75.00 per share, or a lesser number of shares validly tendered and not withdrawn.
Utah Medical Products, Inc. (UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share, or a lesser number if fewer shares are validly tendered and not withdrawn. The offer is subject to the terms and conditions in the Offer to Purchase dated September 24, 2026, and the related Letter of Transmittal. As of September 14, 2026, directors and executive officers as a group were listed with 253,795 total shares and options, or 7.9%.
Utah Medical Products, Inc. is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The offer is scheduled to expire at 5:00 p.m. New York City time on October 7, unless extended by the company. UTMD clarified that October 7 falls on a Wednesday, correcting prior announcements that identified it as Tuesday.
Utah Medical Products, Inc. (UTMD) is offering to purchase up to 650,000 shares of its common stock for $75.00 per share. The company says that price is a 17% premium over the average daily closing price during the last twelve months and a 21% premium over the last twenty-four months. The offer is scheduled to expire at 5:00 p.m. New York City time on October 7, unless UTMD extends it.
UTMD reported first-half 2026 sales and net profits were 12% and 13% lower, respectively, than in the same period of 2025; EBITDA for the most recent twelve months was $15,703,744. The board approved the offer but is making no recommendation on whether shareholders should tender. The company says the offer is intended to provide liquidity for shareholders wishing to sell all or part of their shares.
Utah Medical Products, Inc. (UTMD) is offering to purchase 650,000 shares of its common stock at $75.00 per share, or such lesser number of shares as are validly tendered and not withdrawn.
As of September 14, 2026, 3,173,818 shares of common stock were outstanding.
Utah Medical Products, Inc. (UTMD) announced an issuer self-tender offer to repurchase up to 650,000 shares of its common stock at a fixed price of $75.00 per share, representing approximately 20% of currently outstanding shares, if tendered and not withdrawn on or before October 7.
The offer is priced at a 17% premium to the average daily closing price over the last twelve months and a 21% premium to the two-year average; the highest intraday trading price in the last two years was $75.75. The offer is expected to commence on September 22, 2026, and expire fifteen business days thereafter, unless extended, with odd-lot holders (fewer than 100 shares tendering all shares) given priority and all other tenders subject to pro rata purchase if the offer is oversubscribed. The Board approved the offer but is making no recommendation, and the company indicates it will fund the repurchase from excess cash, stating the objective of enhancing the value of shares held by continuing stockholders via anti-dilution.